POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA approves first treatment for peanut allergy

Christian Fernsby |
The U.S. Food and Drug Administration has approved the first drug to treat peanut allergy, a life threatening condition mainly for kids.

Article continues below




Aimmune Therapeutics's Palforzia can now be used to treat patients aged 4 through 17 years.

Daniel Adelman, chief medical officer of Aimmune, said, "Not only is Palforzia the first approved therapy for peanut allergy, but it is the first approved therapy for any food allergy."

The Palforzia drug reportedly will list for $890 a month.

Peanut allergy, which is one of the most common food allergies in the world, affects more than 1.6 million children and teens in the United States.

In a statement, the biopharmaceutical company developing solutions to treat food allergies said the new drug is an oral immunotherapy or OIT indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental peanut exposure.

With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts. This results in the ability to mitigate allergic reactions to the allergen over time. The new drug's doses contain the equivalent of small amounts of peanuts.

The company said the Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up dosing and maintenance may be continued in patients 4 years of age and older, and the drug is to be used in conjunction with a peanut avoidant diet.

Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy, while it is not indicated for the emergency treatment of allergic reactions, including anaphylaxis.

The company also warned that the new drug can cause life threatening anaphylaxis. Due to this, the drug will be available only through a restricted program under a Risk Evaluation and Mitigation Strategy or REMS called the PALFORZIA REMS.


What to read next

FDA seeks permanent injunctions against two stem cell clinics
Food allergy: Perfect storm of genetics and skin exposure to infant wipes
'Life-changing' Aussie cure for peanut allergies step closer to release